B7-H7: A potential target for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Cancer immunotherapy offers advantages over traditional chemotherapy, including fewer side effects.
• B7-H7 (also known as HHLA2 or B7y) is a B7 family costimulatory molecule expressed in various tissues and immune cells.
• Its expression increases with inflammatory stimuli like lipopolysaccharide and interferon-gamma.

Purpose of the Study:

• To review the current literature on B7-H7 expression, regulation, receptors, and function in tumors.
• To highlight B7-H7 as a potential target for cancer immunotherapy.

Main Methods:

• Literature review of studies on B7-H7 expression, regulation, receptors, and function.
• Analysis of B7-H7's role in tumor progression and immune evasion.

Main Results:

• B7-H7 is upregulated in various human tumors, especially PD-L1-negative ones.
• B7-H7 promotes tumor progression, disrupts anti-tumor immunity, and contributes to immune escape.
• B7-H7 expression correlates with clinical stage, tumor infiltration, metastasis, and patient prognosis.

Conclusions:

• B7-H7 plays a significant role in tumor progression and immune evasion.
• B7-H7 represents a promising target for developing novel cancer immunotherapies.